Elan to use Graffinity's fragment technology for drug discovery
This article was originally published in Scrip
The German company Graffinity Pharmaceutical has entered into a collaboration with ElanPharmaceuticals, which becomes the latest partner for Graffinity's drug discovery technology, which identifies drug fragments that interact with drug targets. Graffinity will receive technology access fees and success payments for generating small molecules, particularly those with novel modes of action and chemistry, for Elan. Graffinity is also collaborating with Rigel, Amgen and Boehringer Ingelheim.
You may also be interested in...
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.